Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | GAPDH | P04406 | 1/20 | 0.39 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.39 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | MSN | P26038 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846777 | 1.00 | GRIN2B (0.41) | GRIN2BAKR1B1CYP4F2CYP4A11TDP1 | |
| SCHEMBL4673771 | 1.00 | GRIN2B (0.41) | GRIN2BAKR1B1CYP4F2CYP4A11TDP1 | |
| SCHEMBL4670515 | 1.00 | GRIN2B (0.41) | GRIN2BAKR1B1CYP4F2CYP4A11TDP1 | |
| SCHEMBL4672232 | 0.89 | SIRT2 (0.44) | GRIN2BAKR1B1CYP4F2CYP4A11MEN1 | |
| SCHEMBL13712678 | 0.86 | AKR1B1 (0.43) | AKR1B1TDP1HSP90AA1GAPDHHSPA1A | |
| SCHEMBL5846863 | 0.84 | CYP4F2 (0.48) | GRIN2BAKR1B1CYP4F2CYP4A11MEN1 | |
| SCHEMBL5846859 | 0.84 | CYP4F2 (0.48) | GRIN2BAKR1B1CYP4F2CYP4A11MEN1 | |
| SCHEMBL5846856 | 0.84 | CYP4F2 (0.48) | GRIN2BAKR1B1CYP4F2CYP4A11MEN1 | |
| SCHEMBL10511215 | 0.81 | CYP4F2 (0.66) | CYP4F2CYP4A11TDP1KMT2AMAPT | |
| SCHEMBL6490826 | 0.81 | MEN1 (0.41) | GRIN2BHSP90AA1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-6903218-B2 | Sulfonamide substituted chroman derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | LADOUCEUR GAETAN H (US) | 2004-04-15 | — | — | US | disclosed |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | BAYER PHARMACEUTICALS CORPORATION | 2003-04-17 | — | — | US | disclosed |
| US-6051586-A | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | BAYER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | GRIN2B 1210/4885AKR1B1 1010/4885CYP4F2 3065/4885 |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | ADRB3, ADRB2, ADRB1 | GRIN2B 747/4885AKR1B1 694/4885CYP4F2 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.